Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor

doi:10.5306/wjco.v14.i9.335

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3663)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1907

Figures (1-1)

184

Tables (1-1)

237

Sum=2446

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

184

Download

382

Sum=566

Publishing Process of This Article

Item

Count

Browse

107

Download

401

Sum=508

Sep 24, 2023 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Sep 24, 2023; 14(9): 335-342
Published online Sep 24, 2023. doi: 10.5306/wjco.v14.i9.335

Full Size Figure Download Figure

Figure 1 Three phases in the chemotherapy drug resistance mechanism caused by pregnane X receptor in triple-negative breast cancer. RXR: Retinal X receptor; PXR: Pregnane X receptor; ABC: Adenosine triphosphate binding cassette; CYPs: Cytochrome P450s; UGTs: Uridine diphosphate glucuronosyltransferase; GSTs: Glutathione transferase.

Citation: Rao ZZ, Tang ZW, Wen J. Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor. World J Clin Oncol 2023; 14(9): 335-342
URL: https://www.wjgnet.com/2218-4333/full/v14/i9/335.htm
DOI: https://dx.doi.org/10.5306/wjco.v14.i9.335